Saudi Alyoom

Global Health doubts the need for a third dose of the “Corona” vaccine

61

The World Health Organization has criticized the issue of the need to give a third dose of Corona vaccines, while hundreds of millions of people have not yet received the first dose in developing countries.

According to the organization, this is due to the financial profit that constitutes a source of huge profits for these companies, especially the pioneering “Pfizer” vaccines in this field, even if the idea of ​​the third dose has been on the table since the beginning of the pandemic, according to what was reported by the newspaper “Al-Sharq al-Awsat”.
These companies have so far provided justifications for giving a third dose, but they are based on ambiguous, ambiguous and incomplete data, in the opinion of the independent scientific community and drug regulatory bodies such as the American and European agencies, which rejected the request for approval and asked the producing company to provide them with more data.

With the unbridled progress of the “delta” mutant, the hypothesis of its ability to resist acquired immunity from vaccines has turned into the desired pretext for companies that produce messenger RNA vaccines, and they have been pressing hard for days to agree to give a third dose to increase immune protection.

The scientific community, which considers that the level of antibodies alone is not sufficient as a basis for making a decision about the third dose, is based on the fact that it is not yet known what level of antibody is needed to avoid infection with the virus or disease.

There is also a recent American study that showed that the antibodies of people who took one dose of the vaccine, do not completely eliminate the “delta” mutator, while the second dose generates enough antibodies to eliminate it. But it is not a clinical study. Rather, it is the result of laboratory experiments in which the virus is implanted in the blood of vaccinated or recovered people from “Covid-19” disease, to measure the ability of antibodies to prevent infection with the virus.

Comments are closed.